Skip to content

Cerebral Autoregulation in Patients With Symptomatic Cerebral Atherosclerotic Stenosis

Cerebral Autoregulation in Patients With Symptomatic Cerebral Atherosclerotic Stenosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05028855
Acronym
CASCAS
Enrollment
850
Registered
2021-08-31
Start date
2017-01-14
Completion date
2026-08-30
Last updated
2024-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Artery Stenosis, Cerebrovascular Stroke

Keywords

cerebral atherosclerotic stenosis, ischemic stroke, transient ischemic attack, cerebral autoregulation

Brief summary

In this multi-center prospective observational study within a cohort of symptomatic cerebral atherosclerotic stenosis (sCAS) patients, 850 subjects were planed to be enrolled to explore the relationship between cerebral autoregulation (CA) and stroke recurrence, determine the threshold values of CA parameter for predicting stroke recurrence associated with particular stenosis.

Detailed description

Ischemic stroke is a tremendous public health burden that seriously endangers the health of Chinese population symptomatic cerebral atherosclerotic stenosis (sCAS) is responsible for about 33-50% of ischemic stroke in China and highly associated with the risk of stroke recurrence. Cerebral autoregulation (CA) is the main protective mechanism that modulates cerebral blood flow to satisfy regional cerebral perfusion demands despite of variations in arterial blood pressure (ABP). Thus, CA supposed to be particularly considered when choosing individual therapeutic strategy in sCAS patients. In clinical practice, applying transcranial Doppler combined with servo-controlled plethysmograph assessing CA has been proved a feasible method in cerebral atherosclerotic stenosis patients. Especially in those severe stenosis patients, CA is probably compromised in varying degrees, whereas whether and to what extent CA parameters have the capability to predict stroke recurrence has not been illustrated. Thus, the aim of the study was to assess CA after acute ischemic stroke or transient ischemic attack within 2 years follow-up to explore the relationship between CA and stroke recurrence and determine the threshold values of CA parameter to predict stroke recurrence. CA measurement will be performed at 0-3 and 10-30 days after ischemic cerebrovascular events. Clinical information, neuroimaging data, biochemical examinations and follow-up information will be collected and recorded in case report form (CRF) once signing of informed consent.

Interventions

DIAGNOSTIC_TESTCerebral autoregulation assessment

Cerebral autoregulation assessment will be conducted by specialized neurovascular ultrasound doctors during 0-3 and 10-30 days after stroke onset.The recorded data will be stored for further cerebral autoregulation analysis.

Sponsors

Shenzhen Second People's Hospital
CollaboratorOTHER
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
CollaboratorOTHER
The First Affiliated Hospital with Nanjing Medical University
CollaboratorOTHER
The First Affiliated Hospital of University of South China
CollaboratorOTHER
Eighth Affiliated Hospital, Sun Yat-sen University
CollaboratorOTHER
The First Affiliated Hospital of Hebei North University
CollaboratorOTHER
Qilu Hospital of Shandong University
CollaboratorOTHER
The Affiliated Hospital of Qingdao University
CollaboratorOTHER
The Affiliated Hospital of Yanbian University
CollaboratorOTHER
Yi Yang
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age ranging from 18 to 80, both genders * Unilateral internal carotid artery (ICA) or M1 segment of middle cerebral artery (MCA) stenosis (rate of stenosis ranging from 50-99%) * Acute ischemic cerebrovascular events (TIA or ischemic stroke) within cerebral stenotic artery supplying area * Onset of disease \<30 d before enrollment * Modified Ranking Scale (mRS) ≤1 before stroke onset * National Institutes of Health Stroke Scale (NIHSS) ≤20 * Sufficient bilateral temporal bone windows for insonation of the middle cerebral artery * Be conscious, and able to cooperate with CA assessment * Willing to participate and sign the informed consent

Exclusion criteria

* Vertebral artery (VA), basilar artery (BA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA) stenosis; Bilateral internal carotid artery (ICA) or M1 segment of middle cerebral artery (MCA) stenosis(rate of stenosis ranging from 50-99%) * Patients who have received or plan to undergo intravascular interventional treatment/endarterectomy * Other intracranial diseases, including cerebral hemorrhage (primary or secondary), intracranial neoplasm, aneurysm, arteriovenous malformation, etc. * Evidence for embolic stroke, such as atrial fibrillation, prosthetic valve surgery, and suspected endocarditis, etc. * Arrhythmia, anemia and hyperthyroidism which may influence the stability of cerebral blood flow diagnosed by two physicians by electrocardiogram and laboratory tests. * Dementia, severe anxiety, depression, and other mental diseases * Malignant neoplasm and expected lifetime \<2 years * Enrolled in other clinical trails within 6 months

Design outcomes

Primary

MeasureTime frameDescription
Stroke recurrence ratetwo yearsIschemic cerebrovascular recurrence (TIA or ischemic stroke) within cerebral stenotic artery supplying area diagnosed by symptoms and imaging examinations.

Secondary

MeasureTime frameDescription
ischemic cerebrovascular recurrence ratetwo yearsAll ischemic cerebrovascular recurrence (TIA or ischemic stroke) within two years follow-up diagnosed by symptoms and imaging examinations.
The first onset time of composite endpoint events within 2 yearstwo years follow-upThe composite endpoint events include fatal and nonfatal stroke (ischemic or hemorrhagic stroke), fatal and nonfatal myocardial infarction, transient ischemic attack (TIA) diagnosed by symptoms and imaging examinations.
The index of cerebral autoregulationwithin 30 days ischemic cerebrovascular events onsetPhase difference, gain and coherence of symptomatic cerebral atherosclerotic stenosis patients within 30 days ischemic cerebrovascular events onset.
The first onset time of each individual part of composite endpoint events within 2 yearstwo years follow-upThe first onset time of each individual part of composite endpoint events within 2 years
the NIHSS scorewithin 1 monthThe changes of NIHSS score from admission to discharge
mRS and Barthel scoretwo yearsThe changes of mRS and Barthel score within 2 years

Countries

China

Contacts

Primary ContactYi Yang, MD, PhD
doctor_yangyi@163.com0086-13756661217
Backup ContactZhenni Guo, MD
zhen1ni2@163.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026